Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response

The long-term effect of protection by two doses of SARS-CoV-2 vaccination in patients receiving chronic intermittent hemodialysis (CIHD) is an urging question. We investigated the humoral and cellular immune response of 42 CIHD patients who had received two doses of SARS-CoV-2 vaccine, and again after a booster vaccine with mRNA-1273 six months later. We measured antibody levels and SARS-CoV-2-specific surrogate neutralizing antibodies (SNA). Functional T cell immune response to vaccination was assessed by quantifying interferon-gamma (IFN-gamma) and IL-2 secreting T cells specific for SARS-CoV-2 using an ELISpot assay. Our data reveal a moderate immune response after the second dose of vaccination, with significantly decreasing SARS-CoV-2-specific antibody levels and less than half of the study group showed neutralizing antibodies six months afterwards. Booster vaccines increased the humoral response dramatically and led to a response rate of 89.2% for antibody levels and a response rate of 94.6% for SNA. Measurement in a no response/low response (NR/LR) subgroup of our cohort, which differed from the whole group in age and rate of immunosuppressive drugs, indicated failure of a corresponding T cell response after the booster vaccine. We strongly argue in favor of a regular testing of surrogate neutralizing antibodies and consecutive booster vaccinations for CIHD patients to provide a stronger and persistent immunity.

Automated summary

A study investigated the long-term effect of two doses of SARS-CoV-2 vaccination in patients receiving chronic intermittent hemodialysis (CIHD). The results showed a moderate immune response after the second dose, but significantly decreasing antibody levels and less than half of the study group showed neutralizing antibodies after six months. Booster vaccines dramatically increased the immune response, with response rates of 89.2% for antibody levels and 94.6% for neutralizing antibodies. In a subgroup with no or low response, there was a failure of corresponding T cell response after the booster vaccine. Regular testing of neutralizing antibodies and consecutive booster vaccinations are strongly recommended for CIHD patients to provide stronger and persistent immunity.